+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Graft Versus Host Disease Treatment Market by Treatment Class (Calcineurin Inhibitors, Corticosteroids, JAK Inhibitors), Route Of Administration (Intravenous, Oral, Subcutaneous), End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Graft Versus Host Disease Treatment Market by Treatment Class (Calcineurin Inhibitors, Corticosteroids, JAK Inhibitors), Route Of Administration (Intravenous, Oral, Subcutaneous), End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Graft Versus Host Disease Treatment Market by Treatment Class (Calcineurin Inhibitors, Corticosteroids, JAK Inhibitors), Route Of Administration (Intravenous, Oral, Subcutaneous), End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5532915
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Graft Versus Host Disease Treatment Market is evolving rapidly as new clinical and regulatory milestones drive novel therapies to the forefront. Senior decision-makers face a shifting landscape shaped by technological innovation, collaborative development, and complex supply chain dynamics. This executive summary delivers structured insights tailored for those responsible for strategic investments and portfolio management within the competitive immunology sector.

Market Snapshot: Graft Versus Host Disease Treatment Market

The global Graft Versus Host Disease Treatment Market expanded from USD 2.06 billion in 2024 to USD 2.28 billion in 2025, and is expected to continue at a 10.55% CAGR to reach USD 3.77 billion by 2030. The field is undergoing transformation due to targeted immunomodulatory therapies, earlier disease detection using advanced biomarkers, and a competitive landscape marked by increased collaboration between academic, biotech, and large pharmaceutical organizations. Regulatory flexibility, coupled with data-driven clinical protocols, supports accelerated therapy approvals and rapid adoption of promising innovations.

Scope & Segmentation

This report delivers granular analysis of the treatment market’s ecosystem. Strategic segmentation provides actionable visibility crucial for optimizing channel strategies and regional investments:

  • Treatment Classes: Calcineurin inhibitors, corticosteroids, JAK inhibitors, monoclonal antibodies
  • Route of Administration: Intravenous, oral, subcutaneous
  • End Users: Ambulatory care centers, hospitals, specialty clinics
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy
  • Geographies: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (featuring United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (covering China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Companies Analyzed: Incyte Corporation, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Mesoblast Limited, Pfizer Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd, Mallinckrodt Pharmaceuticals Company, Merck KGaA

Key Takeaways for Senior Decision-Makers

  • Innovative therapies enable tailored interventions, shifting management away from broad immunosuppression to selective pathways based on immune profiling.
  • Flexible clinical trial frameworks integrating real-world evidence improve enrollment efficiency and inform go/no-go decisions sooner.
  • Strategic partnerships and adaptive trial designs are key levers for competitive differentiation, supporting both early pipeline expansion and late-stage acceleration.
  • Supply chain resilience is now a top concern, with procurement strategies evolving to ensure continuity against policy volatility and shifting global tariff regimes.
  • Regional regulatory differences emphasize the necessity for localized market entry strategies, particularly in Asia-Pacific and emerging EMEA markets where harmonization efforts are improving access dynamics.

Tariff Impact on Industry Operations

Newly implemented US tariffs affect pharmaceutical supply chain costs and sourcing. Companies are reevaluating supplier contracts, shifting to domestic contract manufacturers, and optimizing sourcing to minimize trade disruptions. These measures reinforce the broader industry imperative for integrated procurement and streamlined import/export activities, aligning with efforts to protect margins and ensure stable access to essential materials for therapy production.

Methodology & Data Sources

The report applies a robust methodology, leveraging both primary interviews with clinical and industry experts as well as secondary data from peer-reviewed literature, regulatory filings, and proprietary company sources. Quantitative analysis incorporates validated economic models, industry feedback loops, and expert peer review, ensuring distinct perspectives and balanced recommendations for stakeholders.

Why This Report Matters

  • Equips senior leaders with actionable insights into evolving therapeutic classes, operational threats, and regional growth levers to steer strategy and resource allocation effectively.
  • Delivers a comprehensive, segment-level assessment enabling targeted investment across the product lifecycle and value chain.
  • Informs realignment of manufacturing, sourcing, and partnership approaches in light of current regulatory and trade realities.

Conclusion

The Graft Versus Host Disease Treatment Market is defined by innovation, operational discipline, and region-specific considerations. Decision-makers utilizing this report are positioned to anticipate market shifts and capitalize on new opportunities for therapeutic and commercial success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of post-transplant cyclophosphamide protocols to reduce acute and chronic GvHD incidence
5.2. Emergence of ruxolitinib and other JAK inhibitors as first-line therapies for steroid refractory acute GvHD
5.3. Development of gut microbiome modulation treatments to prevent gastrointestinal manifestations of GvHD
5.4. Expansion of regulatory T cell expansion platforms to restore immune tolerance post-transplant
5.5. Identification and validation of predictive biomarkers for early detection and personalized GvHD management
5.6. Increasing adoption of combination therapies integrating extracorporeal photopheresis with novel immunomodulators for chronic GvHD
5.7. Rising focus on cost-benefit analyses to support reimbursement of emerging GvHD therapies in managed care
5.8. Clinical pipeline emphasis on cell therapies such as mesenchymal stromal cells for steroid-resistant GvHD
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Graft Versus Host Disease Treatment Market, by Treatment Class
8.1. Introduction
8.2. Calcineurin Inhibitors
8.3. Corticosteroids
8.4. JAK Inhibitors
8.5. Monoclonal Antibodies
9. Graft Versus Host Disease Treatment Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Graft Versus Host Disease Treatment Market, by End User
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Hospitals
10.4. Specialty Clinics
11. Graft Versus Host Disease Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Americas Graft Versus Host Disease Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Graft Versus Host Disease Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Graft Versus Host Disease Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Incyte Corporation
15.3.2. AbbVie Inc.
15.3.3. Novartis AG
15.3.4. Bristol-Myers Squibb Company
15.3.5. Mesoblast Limited
15.3.6. Pfizer Inc.
15.3.7. Sanofi S.A.
15.3.8. F. Hoffmann-La Roche Ltd
15.3.9. Mallinckrodt Pharmaceuticals Company
15.3.10. Merck KGaA
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. GRAFT VERSUS HOST DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. GRAFT VERSUS HOST DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. GRAFT VERSUS HOST DISEASE TREATMENT MARKET: RESEARCHAI
FIGURE 24. GRAFT VERSUS HOST DISEASE TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 25. GRAFT VERSUS HOST DISEASE TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 26. GRAFT VERSUS HOST DISEASE TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 53. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 54. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 63. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 64. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 65. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 72. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 73. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 80. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 81. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 88. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 89. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 106. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 114. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 115. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 122. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 123. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 130. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 131. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 138. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 139. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 146. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 147. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 162. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 170. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 178. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 179. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 186. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 187. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 194. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 195. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 202. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 203. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 210. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 211. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 218. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 219. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 226. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 227. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 234. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 235. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 242. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 243. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 250. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 251. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 258. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 259. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 266. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 267. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 274. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 282. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 283. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 284. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 285. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY R

Samples

Loading
LOADING...

Companies Mentioned

  • Incyte Corporation
  • AbbVie Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Mesoblast Limited
  • Pfizer Inc.
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd
  • Mallinckrodt Pharmaceuticals Company
  • Merck KGaA

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.28 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.77 Billion
Compound Annual Growth Rate10.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Graft Versus Host Disease (GvHD) - Pipeline Insight, 2025 - Product Image

Graft Versus Host Disease (GvHD) - Pipeline Insight, 2025

  • Drug Pipelines
  • 180 Pages
  • Global
From
Graft Versus Host Disease (GVHD) Treatment Market Report 2025 - Product Image

Graft Versus Host Disease (GVHD) Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Graft Versus Host Disease (GvHD) Treatment - Global Strategic Business Report - Product Image

Graft Versus Host Disease (GvHD) Treatment - Global Strategic Business Report

  • Report
  • 296 Pages
  • Global
From
Graft Versus Host Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Graft Versus Host Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Graft Versus Host Disease (GVHD) Epidemiology Forecast 2025-2034 - Product Image

Graft Versus Host Disease (GVHD) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From

About the Market

Graft Versus Host Disease (GVHD) is a type of immune disorder that occurs when transplanted donor cells attack the recipient's body. It is a common complication of bone marrow and stem cell transplants. Treatment for GVHD typically involves immunosuppressive drugs, such as corticosteroids, calcineurin inhibitors, and monoclonal antibodies. These drugs are used to reduce inflammation and suppress the immune system, allowing the body to accept the donor cells. The GVHD drug market is a rapidly growing segment of the immune disorder drug market. It is driven by the increasing prevalence of GVHD, as well as the development of new drugs and treatments. The market is expected to continue to grow in the coming years, as more treatments become available and the demand for GVHD drugs increases. Some of the major companies in the GVHD drug market include Novartis, Celgene, Gilead Sciences, and Bristol-Myers Squibb. These companies are involved in the development and marketing of GVHD drugs, as well as other immune disorder drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.